FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to use of N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine (idalopirdine) for preparing a drug for reducing the risk of falls in a patient suffering Parkinson's disease, wherein the treatment additionally involves the introduction of donepezil to said patient. Donepezil dose may range from 1 to 30 mg, the daily dose of idalopirdine 10 to 120 mg.
EFFECT: combination of idalopirdine and donepezil provides a significant reduction in the number of falls in Parkinson's disease.
3 cl, 7 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING VORTIOXETINE AND DONEPEZIL | 2013 |
|
RU2635528C2 |
| COMBINATION OF 5-HT-RECEPTOR ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITOR FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE IN SUBPOPULATION OF PATIENTS THAT ARE CARRIERS OF ApoE4 ALLELES | 2018 |
|
RU2776366C2 |
| MEMANTINE THERAPY FOR ALZHEIMER'S DISEASE OF LOW AND LOW TO MODERATE SEVERITY | 2005 |
|
RU2371173C2 |
| COMPOSITIONS, CONTAINING CHOLINESTERASE INHIBITOR FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2607946C2 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
| METHOD FOR SYNTHESIS OF 2-CARBOXY-N,N,N-TRIMETHYLETHANAMINIUM DERIVATIVE | 2021 |
|
RU2786884C2 |
| 5-HT RECEPTOR AGONIST COMPOUNDS FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2569056C2 |
| DRUG FOR PREVENTION OR TREATMENT OF BRAIN ATROPHY | 2018 |
|
RU2759727C2 |
| INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
| DRUG FOR PREVENTION OR TREATMENT OF TAUPATHY | 2018 |
|
RU2739199C1 |
